News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Melissa Gao

Articles by Melissa Gao

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

BySherene Loi, MD, PhD,Erica Stringer-Reasor,Jean-Sebastien Frenel,Mattea Reinisch,Ruth M. O’Regan,Michelino De Laurentiis,Yeon Hee Park,Anne O’Dea,Yen-Shen Lu,Valeria Gonzalez,Melissa Gao,Sorcha Waters,Huilin Hu,Binghe Xu

June 24th 2025

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

ByNagi El Saghir,Yoon Sim Yap,Yesim Eralp,Seock-Ah Im,Hamdy Abdel Azim,Julie Rihani,Nikita Volkov,Shin-Cheh Chen,Hakan Harputluoglu,Patrapim Sunpaweravong,Yuan-Ching Chang,Teresa Delgar Alfaro,Jiwen Wu,Huilin Hu,Melissa Gao,Yen-Shen Lu

August 15th 2024

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

ByLowell Hart,Seock-Ah Im,Sara M. Tolaney, MD, MPH,Mario Campone,Timothy Pluard,Berta Sousa,Gilles Freyer,Thomas Decker,Kevin Kalinsky, MD, MS,Astrid Thuerigen,Melissa Gao,Huilin Hu,Sherko Kümmel

August 9th 2024

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

ByMelissa Gao,Yen-Shen Lu,Eznal Izwadi Bin Mohd Mahidin,Hamdy Abdel Azim,Yesim Eralp,Yoon Sim Yap,Seock-Ah Im,Julie Rihani,James Bowles,Teresa Delgar Alfaro,Jiwen Wu,Khemaies Slimane,Nagi El Saghir

April 28th 2023

Latest Updated Articles

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
Published: June 24th 2025 | Updated:

Trending on CancerNetwork

Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML

RP2D Dose of Ziftomenib Yields High Response Rates in NPM1-Mutated AML

© 2025 MJH Life Sciences^®

All rights reserved.